首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1746685

2025-2033年日本生物製劑市場報告（依來源、產品、疾病、製造及地區）

Japan Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 121 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本生物製劑市場規模達545億美元。展望未來， IMARC Group預計到2033年，市場規模將達到1,611億美元，2025-2033年期間的複合年成長率（CAGR）為12.16%。精準醫療需求的不斷成長、罕見疾病治療的日益重視以及癌症、類風濕性關節炎、多發性硬化症和慢性發炎等慢性複雜疾病盛行率的上升，是推動市場發展的關鍵因素。

生物製劑涵蓋廣泛的藥物，包括單株抗體、疫苗、基因療法和細胞療法。它們源自活體生物體或其組成部分，例如細胞、蛋白質、基因或組織。它們透過生物技術方法生產，不同於傳統的化學藥物，後者是透過化學過程合成的。它們與體內的特定標靶相互作用以達到治療效果。它們以其高度的特異性和有效性而聞名，通常比傳統藥物副作用更少。它們刺激免疫系統產生免疫反應，而不會引發疾病本身，有助於保護個體免受各種病毒和細菌的侵害。它們可以根據患者疾病的特定基因或分子特徵進行客製化，從而實現個人化治療。它們促進組織再生和傷口癒合，並且與傳統化學藥物相比副作用較少。它們透過增強人體對癌細胞的免疫反應來幫助治療某些類型的癌症。它們有助於治療影響少數族群的罕見疾病和孤兒病。它們用於治療、預防或控制各種疾病。由於生物製劑能夠有效控制症狀和減緩病情進展，從而改善患者的生活品質，因此日本對生物製劑的需求正在上升。

日本生物製劑市場趨勢：

目前，癌症、類風濕性關節炎、多發性硬化症和慢性發炎等慢性複雜疾病在人群中的發生率不斷上升，這是推動日本市場成長的主要因素之一。此外，由於生物製劑降低了住院頻率和嚴重程度，其使用率的上升也促進了日本市場的成長。此外，對精準醫療方法日益成長的需求也為市場帶來了積極的前景。此外，患者對生物製劑益處的認知不斷提高，例如副作用更少、住院時間更短以及療效持久，這為日本的行業投資者提供了豐厚的成長機會。同時，對用於治療癌症的免疫療法和單株抗體的需求不斷成長，也對市場產生了積極的影響。此外，生物生產方法的創新有利於生物製劑經濟高效地生產，這也促進了市場的成長。此外，日本生物製劑臨床試驗數量的增加也推動了市場的成長。此外，大眾對罕見疾病治療的日益關注也推動了市場的成長。生物技術和基因組學技術的進步促進了新型生物製劑的發現和開發，這也支持了日本市場的成長。

日本生物製劑市場細分：

來源洞察：

微生物
哺乳動物
其他

產品洞察：

單株抗體
疫苗
重組蛋白
反義、RNAi 和分子治療
其他

疾病見解：

腫瘤學
免疫系統疾病
心血管疾病
血液系統疾病
其他

製造業洞察：

外包
內部

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本生物製劑市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本生物製劑市場有何影響？
日本生物製劑市場依來源分類是怎樣的？
日本生物製劑市場依產品分類是怎樣的？
日本生物製劑市場依疾病的分類是怎樣的？
日本生物製劑市場依製造方式的分佈如何？
日本生物製劑市場的價值鏈分為哪些階段？
日本生物製劑的主要促進因素和挑戰是什麼？
日本生物製劑市場的結構是怎麼樣的？主要參與者是誰？
日本生物製劑市場的競爭程度如何？

本報告回答的關鍵問題：

日本生物製劑市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本生物製劑市場有何影響？
日本生物製劑市場依來源分類是怎樣的？
日本生物製劑市場依產品分類是怎樣的？
日本生物製劑市場根據疾病的分佈是怎樣的？
日本生物製劑市場依製造方式的分佈如何？
日本生物製劑市場的價值鏈分為哪些階段？
日本生物製劑的主要促進因素和挑戰是什麼？
日本生物製劑市場的結構是怎麼樣的？主要參與者是誰？
日本生物製劑市場的競爭程度如何？

Japan biologics market size reached USD 54.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 161.1 Billion by 2033, exhibiting a growth rate (CAGR) of 12.16% during 2025-2033. The growing demand for precision medicine approaches, increasing focus on treating rare diseases, and rising prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, represent some of the key factors driving the market.

Biologics comprise a wide range of pharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and cell-based therapies. They are derived from living organisms or their components, such as cells, proteins, genes, or tissues. They are produced through biotechnological methods, unlike traditional chemical-based drugs that are synthesized through chemical processes. They interact with specific targets in the body to achieve therapeutic effects. They are known for their high specificity and efficacy, often resulting in fewer side effects compared to conventional drugs. They stimulate the immune system to produce an immune response without causing the disease itself, helping to protect individuals from various viruses and bacteria. They can be tailored to specific genetic or molecular characteristics of disease of patient, enabling personalized treatment approaches. They promote tissue regeneration and wound healing and have fewer side-effects as compared to traditional chemical drugs. They aid in treating certain types of cancer by enhancing the immune response of the body against cancer cells. They assist in addressing rare diseases and orphan diseases that affect a small population. They are used to treat, prevent, or manage various medical conditions and diseases. As they improve the quality of life for patients by effectively managing symptoms and slowing disease progression, the demand for biologics is rising in Japan.

Japan Biologics Market Trends:

At present, the increasing prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, among individuals represents one of the major factors contributing to the market growth in Japan. Moreover, the rising usage of biologics, as they reduce the frequency and severity of hospitalizations, is strengthening the growth of the market in the country. Apart from this, the escalating demand for precision medicine approaches is offering a positive market outlook. Additionally, the increasing awareness among patients about the benefits of biologics, such as fewer side effects, reduced hospital stays, and long-lasting therapeutic effects, is providing lucrative growth opportunities to industry investors in Japan. In line with this, the growing demand for immunotherapies and monoclonal antibodies for treating cancer is influencing the market positively. In addition, innovations in bioproduction methods benefit in cost-effective and efficient production of biologics, which is bolstering the growth of the market. Besides this, the rising number of clinical trials for biologics in the country is propelling the market growth. Furthermore, the increasing focus on treating rare diseases among the masses is impelling the market growth. The technological advancement in biotechnology and genomics enhances the discovery and development of novel biologics, which is also supporting the market growth in Japan.

Japan Biologics Market Segmentation:

Source Insights:

Microbial
Mammalian
Others

Product Insights:

Monoclonal Antibodies
Vaccines
Recombinant Proteins
Antisense, RNAi and Molecular Therapy
Others

Disease Insights:

Oncology
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
Others

Manufacturing Insights:

Outsourced
In-House

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan biologics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan biologics market?
What is the breakup of the Japan biologics market on the basis of source?
What is the breakup of the Japan biologics market on the basis of product?
What is the breakup of the Japan biologics market on the basis of disease?
What is the breakup of the Japan biologics market on the basis of manufacturing?
What are the various stages in the value chain of the Japan biologics market?
What are the key driving factors and challenges in the Japan biologics?
What is the structure of the Japan biologics market and who are the key players?
What is the degree of competition in the Japan biologics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biologics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biologics Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Biologics Market - Breakup by Source

6.1 Microbial
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Mammalian
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Others
- 6.3.1 Historical and Current Market Trends (2019-2024)
- 6.3.2 Market Forecast (2025-2033)

7 Japan Biologics Market - Breakup by Product

7.1 Monoclonal Antibodies
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Vaccines
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Recombinant Proteins
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Antisense, RNAi and Molecular Therapy
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Others
- 7.5.1 Historical and Current Market Trends (2019-2024)
- 7.5.2 Market Forecast (2025-2033)

8 Japan Biologics Market - Breakup by Disease

8.1 Oncology
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Immunological Disorders
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Cardiovascular Disorders
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Hematological Disorders
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
8.5 Others
- 8.5.1 Historical and Current Market Trends (2019-2024)
- 8.5.2 Market Forecast (2025-2033)

9 Japan Biologics Market - Breakup by Manufacturing

9.1 Outsourced
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
9.2 In-House
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)

10 Japan Biologics Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Biologics Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis